ENTA earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -4.77. Updated 2026-07-23.
Enanta Pharmaceuticals (ENTA) Research Hub
Enanta Pharmaceuticals (ENTA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.96 USD (-2.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.77, market cap 0.31B. This hub links to the full technical, earnings and options research available for ENTA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.96 USD (-2.11%) |
| 52-week range | 11.41 USD – 15.51 USD |
| Trend regime | Range |
| 14-day RSI | 41.3 (Bearish) |
| Trailing P/E | -4.77 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ENTA
Covered Call on ENTA: how it works, illustrative setup around the real 12.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENTA: how it works, illustrative setup around the real 12.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENTA: how it works, illustrative setup around the real 12.96 USD price, max profit/loss, breakeven and when to use it. Educational.
ENTA technical analysis: range, last 12.96 USD, RSI 41.3, 52w range 11.41 USD–15.51 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENTA in?
Enanta Pharmaceuticals (ENTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ENTA in an uptrend or downtrend?
As of 2026-09-11, ENTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENTA's trailing P/E ratio?
ENTA's trailing P/E is -4.77, with a market cap of 0.31B. See the earnings research page for full valuation detail.
When does ENTA next report earnings?
ENTA is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.50951 USD.